NeoImmuneTech

Excited to present Neoimmunetech's Phase Ib study results of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR-T cell therapy in DLBCL at the #ESMO2024 mini oral session. Join us on Friday, September 13th at 3:05 PM as Dr. Armin Ghobadi shares the findings. 💡 806MO https://lnkd.in/evpen75v

We’re pleased to share interim results from our Phase 1b clinical trial, presented at #ESMO2024. Our study combining CAR-T therapy with NT-I7 (efineptakin alfa) demonstrates that NT-I7 is safe and effective, significantly boosting CAR-T cell expansion and persistence. This approach may improve outcomes for patients with Large B-cell Lymphoma (LBCL). Find out more about these findings and their potential impact on cancer treatment. 🔗 Read the full press release here https://prn.to/4gjs5hi #Immunotherapy #CAR_T #CancerResearch

Our latest quarterly update highlights significant advancements in immunotherapy: ✅ European Orphan Drug Designation (ODD) - NIT secured European ODD for NT-I7 for the treatment of Acute Radiation Syndrome (ARS). 🔬 Positive clinical trial data - Interim positive results from the NIT-110 study demonstrated improved efficacy of NT-I7 in combination with Keytruda in solid tumors ⭐ SME status - NIT's Polish subsidiary obtained SME status granted by the European Medicines Agency (EMA), facilitating expedited drug development For full details on these updates, read our latest quarterly report https://bit.ly/3xNmHRX

Today we announce the filing of an international patent for our innovative multi-specific antibody platform technology, a significant step forward in our T-cell immunotherapy research. This technology opens doors to innovative treatments.  Read more here https://bit.ly/3VO9Mat

We are thrilled to announce that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to our NT-I7 (efineptakin alfa) for the treatment of Acute Radiation Syndrome (#ARS). This recognition underscores the potential of NT-I7 to address the critical unmet medical need in ARS, following the similar ODD granted by the FDA in the US.   This milestone highlights our commitment to advancing innovative treatments and bringing hope to patients affected by ARS.   🔗 Read the full press release https://prn.to/3Vbw5GQ #AcuteRadiationSyndrome

At #ASCO2024, we presented compelling interim data from our NIT-110 trial. The combination of our T-cell therapy NT-I7 (efineptakin alfa) and pembrolizumab showed significant potential in improving overall survival for patients with pancreatic and colorectal cancer. We're also encouraged by the identification of potential predictive biomarkers and promising preclinical results in glioblastoma. These findings mark another step forward in our mission to bring innovative T cell-focused therapies to patients with hard-to-treat cancers.   🔗 Read the full press release https://prn.to/3UZjPck

Our Polish subsidiary has been granted SME status by the European Medicines Agency (EMA). This milestone enhances our access to finance and EU support programs, accelerating the global development of NT-I7. We're one step closer to providing innovative treatments for idiopathic CD4+ Lymphocytopenia (ICL). https://bit.ly/3yHWUuI

We’re heading to #BIO2024 in San Diego, California, the premier global biotechnology event. Join Luke Oh, our CEO; Tae Woo Kim, CFO; and Daniel Rho, BD Director as they share our latest research, learn from industry leaders, and forge significant partnerships. This is a fantastic opportunity to explore groundbreaking developments in biotechnology that are driving forward the health sector. We are looking forward to connecting with you in San Diego!

Duke University has been awarded a $6 million NIH grant to study the efficacy of NT-I7 in treating Acute Radiation Syndrome. Led by Dr. Benny Chen, this research could substantially improve survival rates and disease outcomes. Discover more about this pivotal advancement in ARS therapy: https://bit.ly/3UytN4h Read our News Update: https://lnkd.in/eU49D_Hb